Pelion invests in DocMorris

Frauenfeld, 20 May 2025 Press release Ad hoc announcement pursuant to Art. 53 LR DocMorris AG (‘DocMorris’) was informed by Pelion S.A. (‘Pelion’), the largest company active in the healthcare sector in Poland, that Pelion has acquired a stake of 9.68% in DocMorris, calculated on the basis of the future number of shares of 51,017,883 after the rights issue. Based on the number of shares before the capital increase of 14,835,093, this corresponds to a stake of 33.27%. DocMorris welcomes that Pelion has made the decision to invest in the company, and is therefore convinced of its potential, being close to the industry with a lot of experience in the pharmacy business. DocMorris had held talks with several potential strategic investors, ahead of the rights issue, including Pelion. According to information on Pelion's website, the privately owned company is headquartered in Lodz, Poland, and has more than 12,000 employees and a turnover of over PLN 18 bn (around CHF 4 bn). Pelion is active in the wholesale of medical products (including medicines), the stationary and online sale of prescription and non-prescription medicines, the supply of hospitals and the provision of logistics services. In addition to Poland, Pelion is also active in Lithuania and Sweden. Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10 Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1 Agenda

19 August 2025	2025 Half-year results (conference call/webcast)
16 October 2025	Q3/2025 Trading update
20 January 2026	Sales 2025
19 March 2026	2025 Full-year results and outlook 2026 (conference call/webcast)
16 April 2026	Q1/2026 Trading update
12 May 2026	Annual General Meeting, Zurich
19 August 2026	2026 Half-year results (conference call/webcast)
15 October 2026	Q3/2026 Trading update

DocMorris The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com. Disclaimer This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Copies of this publication may not be sent to jurisdictions, or distributed in or sent from or otherwise made publicly available in jurisdictions, in which this is barred or prohibited by law. The offer and listing was and will be made solely by means of, and on the basis of, the prospectus published for such purpose. An investment decision regarding any publicly offered securities of the Company should only be made on the basis of such prospectus. The prospectus is available free of charge from UBS AG, Swiss Prospectus Switzerland, P.O. Box, 8098 Zurich, Switzerland (voicemail: +41 44 239 47 03; fax number: +41 44 239 69 14; email: swiss-prospectus@ubs.com).
This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.
This communication does not constitute an "offer of securities to the public" within the meaning of Regulation 2017/1129 of the European Union (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA") or, in the United Kingdom ("UK"), the Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation"). Any offers of the Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the UK Prospectus Regulation (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of the Securities.
The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an applicable exemption from, or in a transaction not subject to the registration requirements of the Securities Act. The issuer of the securities has not registered, and does not intend to register, any portion of the offering in the United States, and does not intend to conduct a public offering of securities in the United States.
This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which is unlawful to do so.
This publication may contain specific forward-looking statements, e.g., statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will", “should”, “plans” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the Company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.